Popular Articles

Human Genome Sciences Announces Completion Of Enrollment In Phase 2b Monthly-Dosing Trial Of Albuferon(R)
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
generic viagra online
Sciele Pharma And Plethora Solutions Announce Positive Results Of Final Phase III Pivotal Trial For PSD502 For Premature Ejaculation
Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE), announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation ("PE") has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time ("IELT"), Index of Premature Ejaculation ("IPE," Ejaculatory Control, Sexual Satisfaction and Distress domains).
News of the day
NHS Should Value The Innovation And Leadership Of Consultants, Says British Medical Association Scotland
BMA Scotland has called on the NHS in Scotland to value the clinical leadership offered by consultants in Scotland in order for patients to benefit from developments and innovations in healthcare. In order to do this, they say, the NHS needs to plan and invest in a consultant workforce that can lead the NHS and deliver the best care for patients.
Sexual Health

AIDS Treatment Activists Push UNAIDS And WHO To Meet Commitments To Reduce HIV In Women And Newborns

In a dramatic meeting today at the UNAIDS headquarters in Geneva, members of the International Treatment Preparedness Coalition (ITPC) and AIDS-Free World met with the leaders and approximately 100 staff members of UNAIDS and WHO to present ITPC"s latest Missing the Target report, Failing Women, Failing Children: HIV, Vertical Transmission and Women"s Health, which identifies the failure of the international community in preventing vertical transmission (also known as prevention of mother-to-child transmission or PMTCT). Citing the research from six countries, ITPC and AIDS-Free World made a strong case that governments and UN agencies have failed to meet their commitment to reduce HIV infection in newborns. In the discussion that followed, almost everyone in the room acknowledged the failure, and Michel Sidibe, Executive Director of UNAIDS issued a call to action to significantly improve delivery of prevention of vertical transmission as a critical step on the road to universal access. "We welcome the personal commitment made by Mr. Sidibe to ensure that the rhetoric to place women at the center of the AIDS response is matched by specific programs and increased budgets. ITPC will continue to monitor governments and UN agencies as they deliver on the goal of universal access," said Aditi Sharma, coordinator of the ITPC report. Speaking on a media conference call after the meeting, Stephen Lewis, co-director of AIDS-Free World, who co-authored the report"s preface, said, "There was tremendous excitement when the idea of preventing vertical transmission was originally put forth, but it has been a matter of some dismay and bewilderment watching the chronicle of lamentable failure ever since. The twin principles which prevention of vertical transmission were meant to embody were universal access on the one hand and gender equality on the other, and both have been vetoed by what has happened -- by the program itself." ITPC"s seventh Missing the Target report presents on-the-ground research conducted by civil society activists in Argentina, Cambodia, Moldova, Morocco, Uganda and Zimbabwe. The report"s researchers highlighted some of the key findings about the provision of prevention of vertical transmission in each of their countries. "Women alone bear the weight of PMTCT and the result of a possible positive HIV test," said Othoman Mellouk, from Morocco. "Many pregnant women, especially those who live in isolated or poor communities, visit a clinic for the first time late in their terms, and may not be tested for HIV or receive information about prevention of vertical transmission," said Lorena Di Giano, from Argentina. "PMTCT is reaching only a handful of Cambodian women and their babies. Only about one in ten HIV-positive mothers and their babies receive antiretroviral drugs to prevent vertical transmission," said Kem Ley, from Cambodia. "In Uganda, many HIV-positive mothers are forced by stigma, poverty or cultural pressures to practice risky mixed-feeding, rather than exclusive breast-feeding, which is safer for their babies," said Richard Hasunira, from Uganda. "HIV-positive women in Moldova who disclose their status and seek treatment and care for themselves and their babies often face stigma and discrimination. They may also face discrimination and violence from their families," said Liudmila Untura, from Moldova. "Many women in Zimbabwe lack the hard currency needed to pay transportation and hospital costs, so more and more of them are delivering their babies at home without expert health care and access to prevention of vertical transmission services," said Caroline Mubaira, from Zimbabwe. The report, published by the Treatment Monitoring and Advocacy Project (TMAP) of ITPC, is based on research conducted in the six countries between November 2008 and January 2009. International Treatment Preparedness Coalition


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):